<DOC>
	<DOCNO>NCT00865189</DOCNO>
	<brief_summary>This study ass efficacy safety two different neoadjuvant treatment approach include Avastin newly diagnose patient high risk locally advanced rectal cancer . Patients randomize one two treatment arm . Arm A undergo induction phase , consist 6 cycle Avastin ( 5mg/kg iv ) plus FOLFOX 4 , follow 7 week chemoradiation phase , consist Avastin ( 5mg/kg iv ) plus 5-FU plus radiotherapy , follow surgery . Arm B omit induction phase , undergo chemoradiation phase follow surgery . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Patients With Newly Diagnosed Locally Advanced Rectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , 1875 year age ; histologically confirm locally advanced rectal cancer ; measurable disease ; ECOG performance status 01 ; prior chemotherapy radiation therapy rectal cancer . prior treatment Avastin ; prior radiotherapy pelvic region , previous cytotoxic chemotherapy ; previous history malignancy ( basal squamous cell cancer skin , situ cancer cervix ) ; history evidence CNS disease ; clinically significant cardiovascular disease ; chronic treatment high dose aspirin ( &gt; 325mg/day ) NSAID .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>